Connect with us

Hi, what are you looking for?

Tuesday, May 30, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


International psychedelics market to reach US$8.31B by 2027: Report Linker

The market was valued at US$4.83B this year and will rise with a CAGR of 14.5 per cent

International psychedelics market will be worth US$8.31B by 2027: Report Linker
Psilocybin mushrooms. Photo by Canna Obscura via Shutterstock

The global market for psychedelic drugs will be worth US$8.3 billion in four years, according to the French market researcher Report Linker.

Report Linker released details from its global psychedelic drugs market report on Wednesday and foresees the market ascending from its current value of US$4.83 billion at a compound annual growth rate of 14.5 per cent.

The list of psychedelic drugs referenced in the report includes psilocybin, MDMA, cannabis, LSD and psychoactive plants like peyote — substances which have promising potential for the treatment of mental health conditions and substance use disorders.

Read more: Mydecine’s MDMA with rapid onset and a short duration shows promising results

Read more: LSD helps alleviate anxiety and major depression symptoms: MindMed

In 2022, North America dominated the market and Report Linker expects that Asia-Pacific will be the most rapidly growing region during the four-year forecast period. Countries covered in the report include Australia, the United States, Brazil, South Korea, China, Russia, India, Germany, Japan and Indonesia.

Report Linker says rising cases of various mental illnesses will propel the market’s growth going forward and says the acquisition of Novamind by Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) for US$20.77 million in 2022 was a significant development for the market.

Numinus is anticipated to expand its psychotherapy clinics in the United States and create sophisticated psychedelic programs as a result of this acquisition. The company saw a 581 per cent increase in year-over-year revenue this February generating US$5.4 million.

Key market players include Johnson & Johnson (NYSE: JNJ), Celon Pharma SA (WSE: CLN), Pfizer Inc. (NYSE: PFE), Compass Pathways PLC (NASDAQ: CMPS), Hikma Pharmaceuticals (LON: HIK), Jazz Pharmaceuticals (NASDAQ: JAZZ), Roche Holding AG Genussscheine (SWX: ROG) and Merck & Co Inc (NYSE: MRK).


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Rowan Dunne on Twitter




Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


The Natural Medicine Health act will take effect on July 1


The group aims to foster EU-funded research on psychedelics and promote drug policies based on scientific evidence


The study has been approved by the Clinical Trials Registry


The survey running until June 2 is sponsored by MAPS, Mind Medicine Australia, SABI Mind and Tiny